Form 4: Vyome Holdings CEO Granted 615K Vested Stock Options

Vyome Holdings, Inc. President and CEO, Nelabhotla Venkateswarlu, was granted 615,149 fully vested stock options following the merger with Vyome Therapeutics.

Summary

• Nelabhotla Venkateswarlu, President and CEO, Director, and 10% Owner of Vyome Holdings, Inc. [HIND], reported a change in beneficial ownership.
• On November 13, 2025, Mr. Venkateswarlu was granted 615,149 stock options to purchase common stock of Vyome Holdings, Inc.
• These options have an exercise price of $0.66 per share and were fully vested as of the grant date.
• The options are exercisable from November 13, 2025, and expire on July 30, 2035.
• This grant is a result of the Agreement and Plan of Merger, dated July 8, 2024, where Raider Lifesciences Inc. merged with Vyome Therapeutics, Inc. on August 15, 2025.
• Following the merger, the Issuer was renamed 'Vyome Holdings, Inc.', and Vyome Therapeutics, Inc. continued as a subsidiary.
• The options were granted under the Issuer's 2025 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of fully vested stock options to a key executive (President and CEO, Director, 10% Owner) following a significant merger is generally a positive signal, indicating management's commitment and alignment with shareholder interests. The immediate vesting suggests confidence and a reward for past or ongoing contributions related to the merger. However, it's a compensation event, not a direct operational or financial performance update.

Positives

• The President and CEO, a significant insider, received a substantial grant of 615,149 fully vested stock options, aligning his interests with shareholders.
• The options were granted at an exercise price of $0.66, providing a clear benchmark for future stock performance.
• The grant is part of the Issuer's 2025 Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Risks

• The value of the stock options is directly tied to the future performance of Vyome Holdings, Inc.'s common stock, exposing the holder to market volatility.
• The success of the merger between Raider Lifesciences Inc. and Vyome Therapeutics, Inc. and the integration of Vyome Therapeutics as a subsidiary will impact the underlying value of the shares.

Future Outlook

The grant of fully vested stock options to the President and CEO, following the recent merger and renaming to Vyome Holdings, Inc., suggests a strategic move to align executive incentives with the long-term growth and success of the newly structured entity. The long expiration date of 2035 provides a significant window for value creation.

Management Comments

• The filing was signed by Venkat Nelabhotla on November 17, 2025.

Industry Context

This transaction reflects a common practice in the biotechnology/pharmaceutical industry, where executive compensation often includes equity incentives to align management's interests with shareholder value, especially post-merger. The merger itself indicates consolidation or strategic expansion within the life sciences sector, a trend often seen as companies seek to leverage synergies and expand pipelines.

Comparison to Industry Standards

• The grant of fully vested options immediately post-merger is a standard practice to incentivize key executives in newly formed or restructured entities, similar to grants observed in recent biotech mergers like the acquisition of Seagen by Pfizer or Horizon Therapeutics by Amgen, where executive retention and motivation are paramount.
• The exercise price of $0.66 per share provides a clear baseline, comparable to how options are priced at or above the market value on the grant date in many public companies to ensure future stock appreciation is required for the options to be 'in the money'.
• The long expiration date of July 30, 2035, is typical for executive stock options, offering a substantial period for the company to achieve its strategic goals and for the stock price to appreciate, aligning with long-term value creation strategies seen across the industry.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The grant of fully vested options to the CEO aligns management's financial interests with shareholder value creation, potentially fostering long-term growth. However, it also represents potential future dilution if options are exercised.
• **Employees:** The mention of a 2025 Equity Incentive Plan suggests a broader framework for employee compensation, which could positively impact morale and retention across the company.

Next Steps

• Continued integration of Vyome Therapeutics, Inc. as a subsidiary of Vyome Holdings, Inc.
• Execution of the Issuer's 2025 Equity Incentive Plan.

Key Dates

Recommendation

The grant of fully vested stock options to the President and CEO is a positive indicator of management's alignment with shareholder interests and confidence in the company's future post-merger. However, this Form 4 filing provides limited information on the company's overall financial health, operational performance, or strategic direction. A 'hold' recommendation is appropriate as this event alone does not provide sufficient data to alter a fundamental investment thesis, but it does offer a favorable signal regarding executive incentives.

Keywords

Vyome Holdings, HIND, Stock Options, Insider Transaction, SEC Form 4, Merger, Equity Incentive Plan, Executive Compensation, Nelabhotla Venkateswarlu, Vyome Therapeutics